The British journal of dermatology
-
Randomized Controlled Trial Multicenter Study
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
The interleukin-17 cytokine family plays a central role in psoriasis pathogenesis. ⋯ Brodalumab therapy resulted in significant clinical benefit and an acceptable safety profile in patients with moderate-to-severe plaque psoriasis.